EGFR and non-small cell lung carcinoma: In some cases of NSCLC expressing mutant EGFR, gefitinib does not inhibit cell proliferation, but PP2 does, collectively suggesting that gefitinib resistance of the mutant EGFR is due to the Src-dependent modulation of EGFR activity.